Organogenesis (NASDAQ:ORGO) Upgraded to “Buy” by BTIG Research

BTIG Research upgraded shares of Organogenesis (NASDAQ:ORGO – Get Rating) from a neutral rating to a buy rating in a research note released on Tuesday, The Fly reports.

Organogenesis Price Performance

NASDAQ:ORGO opened at $3.44 on Tuesday. The firm has a market capitalization of $451.53 million, a price-to-earnings ratio of 31.28 and a beta of 1.52. Organogenesis has a 52-week low of $1.79 and a 52-week high of $6.52. The stock has a fifty day moving average of $2.23 and a 200 day moving average of $2.50. The company has a debt-to-equity ratio of 0.25, a quick ratio of 2.51 and a current ratio of 2.85.

Organogenesis (NASDAQ:ORGO – Get Rating) last posted its quarterly earnings data on Wednesday, March 1st. The company reported $0.06 earnings per share (EPS) for the quarter. The company had revenue of $115.52 million during the quarter. Organogenesis had a return on equity of 8.03% and a net margin of 2.92%.

Insider Activity at Organogenesis

In related news, major shareholder Albert Erani sold 25,000 shares of Organogenesis stock in a transaction on Wednesday, April 12th. The stock was sold at an average price of $2.07, for a total transaction of $51,750.00. Following the completion of the sale, the insider now owns 59,223,027 shares of the company’s stock, valued at $122,591,665.89. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 34.40% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Organogenesis

Hedge funds have recently added to or reduced their stakes in the company. Allspring Global Investments Holdings LLC lifted its stake in Organogenesis by 886.8% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 259,177 shares of the company’s stock worth $697,000 after purchasing an additional 232,913 shares during the last quarter. Point72 Hong Kong Ltd lifted its stake in Organogenesis by 210.9% during the third quarter. Point72 Hong Kong Ltd now owns 18,699 shares of the company’s stock worth $61,000 after purchasing an additional 12,684 shares during the last quarter. Royce & Associates LP bought a new stake in Organogenesis during the third quarter worth about $54,000. Tower Research Capital LLC TRC lifted its stake in Organogenesis by 31.2% during the third quarter. Tower Research Capital LLC TRC now owns 83,319 shares of the company’s stock worth $270,000 after purchasing an additional 19,823 shares during the last quarter. Finally, ExodusPoint Capital Management LP lifted its stake in Organogenesis by 1,095.5% during the third quarter. ExodusPoint Capital Management LP now owns 180,455 shares of the company’s stock worth $585,000 after purchasing an additional 165,360 shares during the last quarter. Institutional investors own 47.03% of the company’s stock.

About Organogenesis

(Get Rating)

Organogenesis Holdings, Inc is a regenerative medical company. It focuses on the development, manufacture and commercialization of product solutions for the advanced wound care, surgical and sports medicine markets. The company was founded in 1985 and is headquartered in Canton, MA.